Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.

Fiche publication

Date publication

juin 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, Melichar B, Bedke J, Pickering L, Fontes-Sousa M, Schmidinger M, Bamias A, Gross-Goupil M, Porta C, Barthélémy P, Escudier B, Albiges L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40516320

Résumé

Adjuvant immunotherapy has remarkably advanced the management of localized renal cell carcinoma (RCC) in patients at high risk of post-surgery recurrence. This Delphi study aimed to establish expert consensus on its use and subsequent management of relapse.